DNA se­quenc­ing gi­ant Il­lu­mi­na bat­tles an­titrust reg­u­la­tors and grow­ing com­pe­ti­tion

July 18, 2022 06:57 AM EDTUpdated July 20, 11:37 AM
Pharma
In Focus

Jared Whitlock

Features Editor

It’s rare for a com­pa­ny to high­light its bur­geon­ing com­pe­ti­tion. But Il­lu­mi­na did just that in a court fil­ing last month.

The San Diego-based com­pa­ny — which makes DNA se­quencers that pow­er every­thing from con­sumer ge­net­ic tests to pre­ci­sion drug de­vel­op­ment — com­mands about 80 per­cent of the mar­ket. The Fed­er­al Trade Com­mis­sion in 2021 cit­ed Il­lu­mi­na’s mar­ket share in chal­leng­ing the com­pa­ny’s ac­qui­si­tion of Grail, a can­cer test­ing com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
A service from the Financial Times